Pharmaceutical Executive March 8, 2024
FDA approves Wegovy (semaglutide) to lower the risk of major adverse cardiovascular events in adults with known heart disease and with either obesity or overweight, in addition to a reduced calorie diet and increased physical activity.
The FDA has expanded the indication of Novo Nordisk’s Wegovy (semaglutide) for lowering the risk of major adverse cardiovascular events (MACE) in adults with known heart disease and with either obesity or overweight, in addition to a reduced calorie diet and increased physical activity.1
Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist, was initially approved in June 2021 for chronic weight management in those with obesity or overweight and at least one weight-related condition, including high blood pressure, type 2 diabetes, or high cholesterol, in...
Today's Sponsors
Today's Sponsor